Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Allison Berger"'
Autor:
Anindya Dutta, Amir A. Jazaeri, Etsuko Shibata, Jonghoon Park, Michael Milhollen, Susan C. Modesitt, Allison Berger, Mark R. Conaway, Jennifer Bryant, Peter G. Smith
Publikováno v:
Molecular Cancer Therapeutics. 12:1958-1967
The nearly ubiquitous development of chemoresistant disease remains a major obstacle against improving outcomes for patients with ovarian cancer. In this investigation, we evaluated the preclinical activity of MLN4924, an investigational inhibitor of
Autor:
Sean A. Beausoleil, Michael Milhollen, Stephen J. Blakemore, Anthony Possemato, Claudia M. Espitia, Pete Smith, Michael P. Thomas, Allison Berger, Steffan T. Nawrocki, Kevin R. Kelly, Jennifer S. Carew
Publikováno v:
Clinical Cancer Research. 19:3577-3590
Purpose: Ovarian cancer has the highest mortality rate of all female reproductive malignancies. Drug resistance is a major cause of treatment failure and novel therapeutic strategies are urgently needed. MLN4924 is a NEDDylation inhibitor currently u
Autor:
Khristofer Garcia, Erik Koenig, Hugues Bernard, Xiaozhen Liu, Eric S. Lightcap, Allison Berger, Jonathan L. Blank, David C. Bouck, Mike Kuranda
Publikováno v:
Cancer Research. 77:1423-1423
Platins are one of the most widely used classes of chemotherapeutic drugs. Although used as part of first-line standard of care regimens for advanced non-small cell lung cancer (NSCLC), their effectiveness remains limited, with a 5-year survival rate
Autor:
Xiaozhen J. Liu, Eric S. Lightcap, Allison Berger, Khristofer Garcia, Jonathan L. Blank, Erik Koenig, David C. Bouck, Mike Kuranda, Hugues Bernard
Publikováno v:
Molecular Cancer Therapeutics. 14:C55-C55
Platinum-based therapies, both cisplatin and carboplatin, are utilized as part of first-line standard of care regimens for advanced non-small cell lung cancer (NSCLC), but overall response rate and overall survival remain limited, with a 5-year survi
Autor:
Michael P. Thomas, Syamala Bandi, Xiaozhen J. Liu, Katherine Cosmopoulos, Eric S. Lightcap, Peter G. Smith, Raymond W. Liu, Khristofer Garcia, Michael D. Pickard, Mike Kuranda, Greg Hather, Allison Berger, David C. Bouck, Jonathan L. Blank
Publikováno v:
Molecular Cancer Therapeutics. 12:B92-B92
MLN4924 is an investigational small molecule inhibitor of the Nedd8-activating enzyme (NAE) currently in Phase 1 clinical trials. MLN4924 induces DNA damage via rereplication in most cell lines. This distinct mechanism of DNA damage may affect its ab
Autor:
Mark R. Conaway, Susan C. Modesitt, Jonghoon Park, Jennifer Bryant, Peter G. Smith, Michael Milhollen, Allison Berger, Amir A. Jazaeri, Anindya Dutta, Etsuko Shibata
Publikováno v:
Cancer Research. 73:3380-3380
Purpose: The objective of this investigation was to evaluate the preclinical activity of MLN4924, an investigational inhibitor of the NEDD8-activating enzyme, against chemoresistant and chemosensitive ovarian cancer cells. ExperimentalDesign: Efficac